StemCell Therapy

Myriad Genetics (NASDAQ: MYGN) and Quotient (NASDAQ:QTNT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Risk & Volatility

Myriad Genetics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Quotient has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.

This table compares Myriad Genetics and Quotients net margins, return on equity and return on assets.

Insider & Institutional Ownership

61.5% of Quotient shares are owned by institutional investors. 6.7% of Myriad Genetics shares are owned by company insiders. Comparatively, 29.0% of Quotient shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Myriad Genetics and Quotient, as reported by MarketBeat.

Myriad Genetics currently has a consensus price target of $30.91, suggesting a potential downside of 20.48%. Quotient has a consensus price target of $11.50, suggesting a potential upside of 30.68%. Given Quotients stronger consensus rating and higher probable upside, analysts plainly believe Quotient is more favorable than Myriad Genetics.

Earnings and Valuation

This table compares Myriad Genetics and Quotients gross revenue, earnings per share and valuation.

Myriad Genetics has higher revenue and earnings than Quotient. Quotient is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Summary

Myriad Genetics beats Quotient on 8 of the 13 factors compared between the two stocks.

About Myriad Genetics

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer. In addition, the company offers myPath Melanoma, a RNA expression test for diagnosing melanoma; myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency; and GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. Further, it provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

About Quotient

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It also develops, manufactures, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to donor collection agencies and testing laboratories, hospitals, independent patient testing laboratories, reference laboratories, blood banking operations, and other diagnostic companies, as well as to original equipment manufacturers. Quotient Limited was founded in 2007 and is based in Penicuik, the United Kingdom.

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
Myriad Genetics (MYGN) versus Quotient (QTNT) Head-To-Head ...

This entry was posted on June 26, 2018 at 8:45 am and is filed under Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |